THL Partners is set to acquire Celerion from H. I. G.

Capital in a transaction valued at $1.8 billion, according to recent industry reports and official announcements. Celerion, established in 2010 and headquartered in Lincoln, Nebraska, operates as a global provider specializing in clinical pharmacology and bioanalytical sciences, serving the pharmaceutical and biotechnology sectors. The acquiring firm, THL Partners, is a Boston-based private equity firm founded in 1974 that focuses on investments in middle-market growth companies.

This acquisition marks a significant move within the healthcare and life sciences private equity landscape, reflecting continued investor interest in clinical research organizations (CROs) and related service providers. While the article confirms the purchase price and the parties involved, further details regarding the closing timeline or specific strategic rationale for the deal were not immediately available in the provided excerpt. The transaction underscores the substantial valuation being placed on specialized clinical research infrastructure as the demand for efficient drug development pathways remains high.